# Galderma R&D clinical trials: 284 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 284 trials with Galderma R&D as lead sponsor, 11 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Galderma R&D: 284 rows for $14.20, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/galderma-r-and-d

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 284
- Recruiting or not yet: 11
- Read on: November 19, 2026

## Trials

The 25 newest of 284, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 2, 2026 | NCT07909421 | A Study to Evaluate the Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction of Midface Contour Deficiencies | Galderma R&D | Not applicable | Not yet recruiting | Cheek Wrinkles, Midface Contour Deficiencies | 326 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909421) |
| October 23, 2026 | NCT07891767 | A Study to Evaluate the Long-term Safety and Effectiveness of Sculptra™ | Galderma R&D | Observational | Recruiting | Midface Volume Deficit, Midface Contour Deficiency | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891767) |
| September 4, 2026 | NCT07805512 | A Study to Evaluate the Effectiveness and Safety of Restylane Shaype in the Improvement of Jawline Definition | Galderma R&D | Not applicable | Recruiting | Jawline Definition | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805512) |
| August 13, 2026 | NCT07762833 | Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis | Galderma R&D | Phase 3 | Recruiting | Atopic Dermatitis | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762833) |
| June 22, 2026 | NCT07660835 | Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis | Galderma R&D | Phase 2 | Recruiting | Moderate-to-Severe Atopic Dermatitis | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07660835) |
| May 5, 2026 | NCT07566286 | Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region | Galderma R&D | Not applicable | Recruiting | Chin Augmentation | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566286) |
| February 10, 2026 | NCT07399028 | A Study to Characterize Human Skin Changes From Biostimulator Treatments Via Non-invasive Imaging | Galderma R&D | Not applicable | Recruiting | Volume Deficiency in the Mid-Face, Skin Laxity, Photo-aged Skin | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07399028) |
| February 10, 2026 | NCT07398989 | A Clinical Study to Assess Efficacy and Tolerability of a Topical Skincare Product on Adults With Mature, Crepey Skin | Galderma R&D | Phase 4 | Completed | Crepey Skin, Aging Skin, Photo-aged Skin | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07398989) |
| January 15, 2026 | NCT07344584 | A Prospective Pilot Study to Evaluate Safety and Effectiveness of GP0122 and GP0124 for Correction of Lines and Wrinkles in the Cheek Area | Galderma R&D | Not applicable | Active not recruiting | Wrinkle Reduction | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07344584) |
| January 15, 2026 | NCT07342400 | A Clinical Study to Assess Histological Changes From Treatment of Poly L-lactic Acid Biostimulator on Women at Various Menopausal Stages | Galderma R&D | Not applicable | Recruiting | Cheek Wrinkles, Menopausal Women | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07342400) |
| September 22, 2025 | NCT07186413 | A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris | Galderma R&D | Phase 3 | Active not recruiting | Acne Vulgaris | 561 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07186413) |
| July 20, 2025 | NCT07074977 | Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin... | Galderma R&D | Phase 2 | Active not recruiting | Chronic Pruritus of Unknown Origin | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07074977) |
| July 2, 2025 | NCT07047690 | A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis | Galderma R&D | Phase 2 | Recruiting | Systemic Sclerosis | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07047690) |
| July 2, 2025 | NCT07047638 | A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine | Galderma R&D | Not applicable | Active not recruiting | Skin Quality Improvement | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07047638) |
| May 25, 2025 | NCT06988618 | Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults | Galderma R&D | Observational | Recruiting | Prurigo Nodularis | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06988618) |
| May 25, 2025 | NCT06988605 | Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults | Galderma R&D | Observational | Recruiting | Atopic Dermatitis | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06988605) |
| October 30, 2024 | NCT06665477 | Evaluate the Effectiveness and Safety of Restylane Volyme in the Treatment of Temple Hollowing | Galderma R&D | Not applicable | Completed | Temple Hollowing | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06665477) |
| May 24, 2024 | NCT06428214 | A Restylane Treatment Algorithm Approach for Participants With Appearance of Insufficient Bone Structure in the Lower Face Alone or in... | Galderma R&D | Not applicable | Completed | Chin Augmentation | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06428214) |
| April 18, 2024 | NCT06372782 | Comparing Pain, Safety and Effectiveness of Restylane Skinboosters Vital Lido and Vital Without Lido in Dorsal Hand | Galderma R&D | Not applicable | Completed | Skin Aging of Dorsal Hands | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06372782) |
| April 10, 2024 | NCT06357221 | A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients | Galderma R&D | Phase 4 | Completed | Plaque Psoriasis, Psoriasis | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06357221) |
| April 8, 2024 | NCT06351358 | Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies | Galderma R&D | Not applicable | Completed | Photoaging, Weight Loss, Skin Laxity, Photodamaged Skin, Volume Deficiency of the Midface | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06351358) |
| April 8, 2024 | NCT06351293 | A Comparative Analysis of Two Hyaluronic Acid Fillers for Nasolabial Fold Correction | Galderma R&D | Not applicable | Completed | Wrinkle | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06351293) |
| December 7, 2023 | NCT06161246 | A Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction | Galderma R&D | Phase 4 | Completed | Injection Site Discomfort | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06161246) |
| August 29, 2023 | NCT06015217 | A Clinical Study to Assess the Efficacy and Safety of a Healing Ointment on Diaper Rash | Galderma R&D | Phase 4 | Completed | Diaper Rash | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06015217) |
| August 14, 2023 | NCT05987163 | Study to Evaluate the Safety and Effectiveness of GP0116 | Galderma R&D | Not applicable | Active not recruiting | Skin Manifestations | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05987163) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 7 |
| Phase 2 | 34 |
| Phase 2/3 | 1 |
| Phase 3 | 67 |
| Phase 4 | 73 |
| Not applicable | 86 |
| Observational | 16 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 257 |
| Recruiting | 10 |
| Active not recruiting | 6 |
| Terminated | 5 |
| Withdrawn | 4 |
| Not yet recruiting | 1 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Acne Vulgaris | 45 |
| Rosacea | 24 |
| Dermatitis, Atopic | 13 |
| Keratosis, Actinic | 10 |
| Psoriasis | 8 |
| Skin Manifestations | 5 |
| Carcinoma, Basal Cell | 5 |
| Onychomycosis | 4 |
| Osteoarthritis, Knee | 4 |
| Melanosis | 4 |
| Foot Dermatoses | 3 |
| Pruritus | 3 |
| Erythema | 3 |
| Cellulite | 2 |
| Atrophy | 2 |
| Prurigo | 2 |
| Neurodermatitis | 2 |
| Skin Diseases | 2 |
| Alopecia | 2 |
| Bowen's Disease | 2 |
| Cutis Laxa | 2 |
| Lipodystrophy | 1 |
| Metatarsalgia | 1 |
| Funnel Chest | 1 |
| Behavior | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Threads and yarns wholesalers in the United States](https://specstream.ai/data/businesses/threads-and-yarns-wholesalers/united-states)
- [Food and beverage exporters in the United States](https://specstream.ai/data/businesses/food-and-beverage-exporters/united-states)
- [Tax preparation firms in the United States](https://specstream.ai/data/businesses/tax-preparation-firms/united-states)
- [Fingerprinting services in the United States](https://specstream.ai/data/businesses/fingerprinting-services/united-states)
- [Stucco contractors in the United States](https://specstream.ai/data/businesses/stucco-contractors/united-states)
- [Farm equipment repair companies in the United States](https://specstream.ai/data/businesses/farm-equipment-repair-companies/united-states)
